Aprea Therapeutics (APRE) – Press Releases
-
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
-
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
-
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
-
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
-
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
-
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
-
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
-
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
-
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
-
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
-
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfo
-
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
-
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
-
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
-
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
-
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
-
Aprea Therapeutics to Present at BIO International Convention
-
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
-
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
-
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
-
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
-
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
-
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
-
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
-
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
-
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
-
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
-
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
-
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
-
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
-
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
-
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
-
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
-
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
-
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
-
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
-
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
-
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
-
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
-
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
-
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
-
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
-
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
-
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
-
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
-
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
Back to APRE Stock Lookup
